Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer
- 1 July 2021
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 563, 40-46
- https://doi.org/10.1016/j.bbrc.2021.05.066
Abstract
No abstract availableKeywords
Funding Information
- Ogun Ministry of Education Science and Technology
- Korea Health Industry Development Institute
- National Research Foundation of Korea
This publication has 23 references indexed in Scilit:
- Latest research and treatment of advanced-stage epithelial ovarian cancerNature Reviews Clinical Oncology, 2013
- Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2Cell Cycle, 2011
- Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2Cancer Research, 2011
- Natural Killer Cell Education and ToleranceCell, 2010
- Functions of natural killer cellsNature Immunology, 2008
- Cancer Immunosurveillance and Immunoediting: The Roles of Immunity in Suppressing Tumor Development and Shaping Tumor ImmunogenicityAdvances in Immunology, 2006
- NK CELL RECOGNITIONAnnual Review of Immunology, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Activating Receptors and Coreceptors Involved in Human Natural Killer Cell-Mediated CytolysisAnnual Review of Immunology, 2001
- Combination therapy with cisplatin: Modulation of activity and tumour sensitivityClinical Oncology, 1992